Abstract
Background: We aimed to describe the real-world effectiveness and safety of the oral JAK inhibitor tofacitinib (tofa) in Crohn's disease (CD). Methods: We analyzed a retrospective, multi-center cohort from 3 IBD referral centers in the United States. CD pts started on tofa for active disease were included. The primary outcome was clinical response (> 50% reduction in symptoms) at week 8 determined by physician global assessment. Secondary outcomes included clinical remission at week 8. Adverse events (AEs) were recorded. Abnormal lipid..
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
